Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

The rapid expansion of the available genomic data continues to greatly impact biomedical
science and medicine. Fulfilling the clinical potential of genetic discoveries requires the …

Cardiovascular diseases are the leading cause of death globally and are associated with
increasing financial expenditure. With the availability of next-generation sequencing …

The deeper understanding of non-coding RNAs has recently changed the dogma of
molecular biology assuming protein-coding genes as unique functional biological effectors …

Viral infections, in addition to damaging host cells, can compromise the host immune
system, leading to frequent relapse or long-term persistence. Viruses have the capacity to …

Connective tissue growth factor (CTGF) is a key signaling and regulatory molecule involved
in different biological processes, such as cell proliferation, angiogenesis, and wound …

Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely
used strategy for treating malignant tumors. However, most intracellular proteins have been …

The RIG‐I pathway can be activated by RNA containing 5′ triphosphate, leading to type I
interferon release and immune activation. Hence, RIG‐I agonists have been used to induce …

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the
gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative …

To stop the spread of future epidemics and meet infant vaccination demands in low‐and
middle‐income countries, flexible, rapid and low‐cost vaccine development and …